3-fluoro-2,2-dimethylbutane | 92089-78-6

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 英文名称: 3-fluoro-2,2-dimethylbutane
• 英文别名: 3,3-dimethyl-2-fluorobutane
• CAS: 92089-78-6
• 化学式: C₆H₁₃F
• 分子量: 104.168
• InChiKey: AOBXEFKIIYQSSJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3,3-二甲基-2-丁醇 在 pyridinium polyhydrogenfluoride 、 氢氟酸 作用下， 以 正庚烷 为溶剂， 反应 4.0h， 生成 2-氟-2,3-二甲基丁烷 、 3-fluoro-2,2-dimethylbutane
  参考文献：
  名称：

  Fluorination of alkanes by chlorine trifluoride. Hydride abstraction mechanism

  摘要：

  DOI：

  10.1021/jo00381a017

文献信息

• Process for producing fluoro-compounds
  申请人：Kondo Norihisa

  公开号：US20090030228A1

  公开（公告）日：2009-01-29

  The present invention provides a process for producing highly pure fluoro-compounds by making use of less costly and readily handleable N-(2-chloro-1,1,2-trifluoroethyl)diethylamine. The process produces little or no chlorinated by-products. Specifically the present invention provides a process for producing a fluoro-compound, comprising fluorinating an alcohol derivative represented by the following general formula (1): R 1 R 2 R 3 COH  (1) (wherein R 1 represents a hydrogen atom, a substituted or unsubstituted alkyl group, aryl group, alkylcarbonyl group, alkoxycarbonyl group, arylcarbonyl group or aryloxycarbonyl group; and R 2 and R 3 are each independently a substituted or unsubstituted alkyl group, aryl group, alkylcarbonyl group, alkoxycarbonyl group, arylcarbonyl group or aryloxycarbonyl group, wherein at least two of R 1 , R 2 and R 3 may together form part of a ring structure, either with or without a heteroatom) with N,N-diethyl-2-chloro-1,1,2-trifluoroethylamine to form a fluoro-compound represented by the following general formula (2): R 1 R 2 R 3 CF  (2) (wherein R 1 , R 2 and R 3 are as defined above), the process being characterized in that an alcohol derivative represented by the following general formula (3): R 4 OH  (3) (wherein R 4 represents a substituted or unsubstituted alkyl group or aryl group) is added to the reaction system.

  本发明提供了一种利用成本较低且易于处理的N-(2-氯-1,1,2-三氟乙基)二乙胺生产高纯度氟化合物的方法。该方法几乎不产生氯化副产物。具体而言，本发明提供了一种生产氟化合物的方法，包括将由下述通式(1)表示的醇衍生物进行氟化：R1R2R3COH (其中R1代表氢原子、取代或未取代的烷基、芳基、烷基羰基、烷氧羰基、芳基羰基或芳氧羰基；R2和R3分别独立地代表取代或未取代的烷基、芳基、烷基羰基、烷氧羰基、芳基羰基或芳氧羰基，其中R1、R2和R3中的至少两个可以共同形成环结构，带有或不带有杂原子)与N,N-二乙基-2-氯-1,1,2-三氟乙基胺反应，形成由下述通式(2)表示的氟化合物：R1R2R3CF (其中R1、R2和R3如上所定义)，其特征在于向反应体系中加入由下述通式(3)表示的醇衍生物：R4OH (其中R4代表取代或未取代的烷基或芳基)。
• DIHYDROPYRIMIDO LOOP DERIVATIVE AS HBV INHIBITOR
  申请人：MEDSHINE DISCOVERY INC.

  公开号：US20170197986A1

  公开（公告）日：2017-07-13

  Disclosed is a dihydropyrimido fused ring derivative as a HBV inhibitor, and in particular relates to a compound shown as formula (I) or a pharmaceutically acceptable salt thereof.

  本发明公开了一种二氢嘧啶并环衍生物作为HBV抑制剂，特别涉及一种如下式（I）所示的化合物或其药用可接受的盐。
• Heterocyclic Compounds and Methods of Use
  申请人：Medivation Technologies LLC

  公开号：US20180051013A1

  公开（公告）日：2018-02-22

  This disclosure provides compounds and methods of using those compounds to treat metabolic disorders and hyperproliferative disorders, including administration of the compounds in conjunction with hormone receptor antagonists.

  这份披露提供了化合物和使用这些化合物治疗代谢性疾病和增生性疾病的方法，包括与激素受体拮抗剂一起给予这些化合物的方法。
• SMALL MOLECULE MODULATORS OF CELL ADHESION
  申请人：Gupta Mukur

  公开号：US20090291967A1

  公开（公告）日：2009-11-26

  Compounds, particularly compounds having activity as modulators of cadherin-mediated cell adhesion having the following structure: or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , A, X, Y, Z, m and n are as defined herein. Methods associated with preparation and use of the same, as well as pharmaceutical compositions containing the same, are also disclosed.

  化合物，特别是具有作为调节cadherin介导的细胞粘附活性的化合物，具有以下结构：或其药用盐、立体异构体或前药，其中R1、R2、R3、R4、R5、R6、A、X、Y、Z、m和n如本文所定义。与其制备和使用相关的方法，以及含有该化合物的药物组合物也被披露。
• HETEROCYCLIC COMPOUNDS AND METHODS OF USE
  申请人：Medivation Technologies, Inc.

  公开号：US20150065519A1

  公开（公告）日：2015-03-05

  This disclosure provides compounds and methods of using those compounds to treat metabolic disorders and hyperproliferative disorders, including administration of the compounds in conjunction with hormone receptor antagonists.

  本公开提供了化合物及其使用方法，用于治疗代谢性疾病和增生性疾病，包括与激素受体拮抗剂一起给予化合物的治疗方法。